GCP
RVNC

GSA Capital Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

GSA Capital Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,819
Closed -$108K – 2109
2024
Q3 		$108K Buy
+20,819
New +$103K 0.01% 1481
2023
Q1 		– Sell
-45,659
Closed -$843K – 2005
2022
Q4 		$843K Buy
+45,659
New +$1.04M 0.1% 289
2022
Q3 		– Sell
-42,978
Closed -$594K – 1937
2022
Q2 		$594K Sell
42,978
-24,254
-36% -$373K 0.09% 389
2022
Q1 		$1.31M Buy
+67,232
New +$1.02M 0.18% 97
2021
Q3 		– Sell
-24,498
Closed -$726K – 1845
2021
Q2 		$726K Buy
+24,498
New +$707K 0.08% 392
2020
Q2 		– Sell
-30,574
Closed -$452K – 1198
2020
Q1 		$452K Buy
+30,574
New +$632K 0.11% 220
2019
Q1 		– Sell
-10,451
Closed -$210K – 1745
2018
Q4 		$210K Buy
+10,451
New +$230K 0.02% 1077
2018
Q3 		– Sell
-14,800
Closed -$406K – 1961
2018
Q2 		$406K Buy
+14,800
New +$445K 0.02% 1253

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

GSA Capital Partners's RVNC Position: Q4 2024 in Review

GSA Capital Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 20,819 shares — an estimated $108K sold.

GSA Capital Partners first reported a position in RVNC in Q2 2018 and held it in 8 quarters. The position peaked at $1.31M in Q1 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • GSA Capital Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 20,819 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $108K.
  • GSA Capital Partners first reported a position in Revance Therapeutics, Inc. in Q2 2018 and held it in 8 quarters.
  • GSA Capital Partners's Revance Therapeutics, Inc. position peaked at $1.31M in Q1 2022.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.